Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.10.5319

Clinical Safety and Efficacy of Kanglaite® (Coix Seed Oil) Injection Combined with Chemotherapy in Treating Patients with Gastric Cancer  

Zhan, Yi-Ping (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Cao, Jie (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Lu, Yan-Yan (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Wu, Xue-Yan (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Liu, Jin (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Xu, Xia (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
Xiang, Jin (Department of Research, Jiangsu Cancer Hospital & Research Institute)
Ye, Li-Hong (Nanjing University of Traditional Chinese Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.10, 2012 , pp. 5319-5321 More about this Journal
Abstract
Objective: To observe efficacy and side effects, as well as the impact on quality of life, of Kanglaite$^{(R)}$ (Coix Seed Oil) injections combined with chemotherapy in the treatment of advanced gastric cancer patients. Method: A consecutive cohort of 60 patients were divided into two groups: the experimental group receiving Kanglaite$^{(R)}$ Injection combined with chemotherapy and the control group with chemotherapy alone. After more than two courses of treatment, efficacy, quality of life and side effects were evaluated. Results: The response rate and KPS score of experimental group were significantly improved as compared with those of the control group (P<0.05). In addition, gastrointestinal reactions and bone marrow suppression were significantly lower than in the control group (P<0.05). Conclusions: Kanglaite$^{(R)}$ Injection enhanced efficacy and reduced the side effects of chemotherapy, improving quality of life of gastric cancer patients; use of Kanglaite$^{(R)}$ injections deserves to be further investigated in randomized control clinical trails.
Keywords
Kanglaite injection; chemotherapy; advanced gastric cancer treatment;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Clancey JK (1995). Karnofsky performance scale. J Neurosci Nurs, 27, 220.
2 Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.   DOI   ScienceOn
3 Friendlander AH, Ettinger RL (2009). Karnofsky performance status scale. Spec Care Dentist, 29, 147-8.   DOI
4 Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
5 Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.   DOI
6 Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
7 Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
8 Kaba H, Fukuda H, Yamamoto S, Ohashi Y (2004). [Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0]. Gan To Kagaku Ryoho, 31, 1187-92.
9 Lian Z, Lu Y, Hou E, Wang X (2006). [Combination of GP regimen and Kanglaite in the treatment of advanced nonsmall cell lung cancer]. Zhongguo Fei Ai Za Zhi, 9, 74-7.
10 Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
11 Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
12 Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
13 Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.   과학기술학회마을   DOI
14 Li D (2005). [The anticancer drug Kang-Lai-Te emulsion for infusion]. Vestn Ross Akad Med Nauk, 9, 32-7.
15 Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.   과학기술학회마을   DOI
16 Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.   과학기술학회마을   DOI
17 Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
18 Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
19 Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
20 Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.   과학기술학회마을   DOI
21 Yan PW, Huang XE, Jiang Y, et al (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
22 Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
23 Yao CY, Huang XE, Tang JH, et al (2010). Clinical observationson safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
24 Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.   과학기술학회마을   DOI
25 Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
26 Zhang XZ, Huang XE, Xu YL, et al (2012). APhase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.   DOI
27 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
28 Zhu L, Yang Z, Wang S, Tang Y (2009). [Kanglaite for Treating Advanced Non-small-cell Lung Cancer: A Systematic Review.]. Zhongguo Fei Ai Za Zhi, 12, 208-15.